Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.An evaluation of androgen receptor expression in benign prostatic hyperplasia, prostatic intraepithelial neoplasia and prostatic adenocarcinoma
Researchers from India have identified differential nuclear expression of the androgen receptor (AR) in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma.1
ARs regulate the activity of androgens, primarily testosterone and 5-α-dihydrotesterone, which play vital roles in the maintenance of prostate tissue. The AR also contributes to the development of benign and malignant prostatic lesions.1
Prostate cancer tissue from patients with adenocarcinoma or PIN exhibited increased AR staining compared to BPH.1
Prostatic tissue (formalin fixed-paraffin embedded) from 25 cases underwent specific AR immunostaining; 10 BPH cases, 5 cases of PIN and 10 prostatic adenocarcinoma cases.1
Increased intensity of AR staining was observed in well-differentiated tumours compared with less well-differentiated tumours.1
Husain and colleagues found that staining observed for prostate cancer cases was heterogeneous and variable. However, they also noted that, potentially due to the small study size, the increased AR staining in prostate cancer compared to BPH was not statistically significant.1
From these findings, the investigators suggest that AR may be a potential prognostic marker for prostate cancer.1
